- Home
- Kostenlose App-Analyse
- Pharmacist's Letter
- Pharmacist's Letter Vs. PneumoRecs VaxAdvisor
Pharmacist's Letter im Vergleich zu PneumoRecs VaxAdvisor Nutzung und Statistiken
Get all the benefits of Pharmacist’s Letter, including CE, on the go. Pharmacist’s Letter from TRC Healthcare is vetted by clinicians to provide top-of-mind recommendations on the latest clinical findings in medication therapy.
Pharmacist's Letter includes:
• 12 issues every year, with concise, evidence-based recommendations about new medications and updated guidelines
• The largest CE library available to fulfill state-specific requirements, including new live and on-demand courses each month
• Clinical charts and other resources with actionable advice
- Apple App Store
- Kostenlos
- Medizin
Rang speichern
- -
This is the PneumoRecs VaxAdvisor App created by the Centers for Disease Control and Prevention (CDC) in collaboration with the Georgia Tech Research Institute. PneumoRecs VaxAdvisor provides patient-specific pneumococcal vaccination guidance consistent with the pneumococcal vaccination recommendations of the Advisory Committee on Immunization Practices. Vaccination providers enter a patient’s age and respond to prompts about the patient’s pneumococcal vaccination history and underlying medical conditions. The app then displays patient-specific pneumococcal vaccination recommendations consistent with the recommended U.S. immunization schedule.
- Apple App Store
- Kostenlos
- Medizin
Rang speichern
- -
Pharmacist's Lettervs. PneumoRecs VaxAdvisor Ranking-Vergleich
Vergleichen Sie Pharmacist's Letter den Ranking-Trend der letzten 28 Tage mit PneumoRecs VaxAdvisor
Rang
Keine Daten verfügbar
Pharmacist's Letter im Vergleich zu PneumoRecs VaxAdvisor Ranking im Ländervergleich
Vergleichen Sie Pharmacist's Letter den Ranking-Trend der letzten 28 Tage mit PneumoRecs VaxAdvisor
Alle Kategorien
Keine Daten verfügbar
Medizin
Stellen Sie mit unserer kostenlosen Testversion Vergleiche mit jeder Website an
Pharmacist's Letter VS.
PneumoRecs VaxAdvisor
Januar 18, 2025